What is the drug classification of tigecycline?
Tigecycline is used to treat certain serious bacterial infections when other antibiotics may not work. It is related to a class of drugs known as tetracycline antibiotics. It works by stopping the growth of bacteria.
What is the use of tigecycline?
Tigecycline injection used to treat certain serious infections including community acquired pneumonia (a lung infection that developed in a person who was not in the hospital), skin infections, and infections of the abdomen (area between the chest and the waist).
What is the mode of action of tigecycline?
Tigecycline’s antibacterial mechanism of action is similar to that of older tetracyclines. It works by inhibiting bacterial protein synthesis by binding to bacterial 30S ribosomal subunits, ultimately blocking entry of aminoacyl transfer RNA molecules into the A site of the ribosome.
Which of the following is the most appropriate indication for tigecycline tygacil use?
TYGACIL is indicated in patients 18 years of age and older for the treatment of complicated skin and skin structure infections caused by susceptible isolates of Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates), Staphylococcus aureus (methicillin-susceptible and -resistant isolates).
What happens when tigecycline given to children?
No serious adverse events were detected in these very ill children. Twenty cases of children treated with tigecycline were previously published, mostly for multidrug-resistant/XDR bacteria. An episode of acute pancreatitis and neutrophil engraftment delay in 2 cases were reported during tigecycline treatment.
Which of the following is the most appropriate indication for tigecycline Tygacil use?
What is the half life of tigecycline?
Tigecycline has an elimination half-life of approximately 36 hours (1, 3). It is mainly eliminated as unchanged drug and metabolites in the bile and feces (59%).
Can tigecycline be used in renal failure?
Tigecycline was not efficiently removed by dialysis; thus, it can be administered without regard to timing of hemodialysis. Based on these pharmacokinetic data, tigecycline requires no dosage adjustment in patients with renal impairment.
Has tigecycline resistance been reported in clinical isolates?
Tigecycline resistance often occurs during the clinical treatment of CRKP, yet its mechanism has still not been clearly elucidated. This study presents an analysis of a tigecycline resistance mechanism that developed in clinical isolates from a 56-year-old female patient infected with CRKP during tigecycline treatment.
What covers tigecycline?
Coverage includes many multidrug-resistant strains of gram-positive organisms, such as MRSA and MRSE, penicillin-resistant Streptococcus pneumoniae, and VRE species. Tigecycline has also shown activity against organisms that have developed resistance to tetracycline via various mechanisms.